DaVita reported $14.0B of revenue over the trailing twelve months, +6.4% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $14.0B (to Q2 2026). Net income: $847M, trailing twelve months to Q2 2026. Free cash flow: $1.61B, trailing twelve months to Q2 2026. Operating margin: 15%, trailing twelve months to Q2 2026.

DVADaVita

Healthcare

$179.29+38% 1Y

$179.29

$103.8752 weeks$239.50

DVA as reported

DaVita reported $14.0B of revenue over the trailing twelve months, +6.4% on the year before. 10 reported series are charted on this page, each one as filed.

$14.0B

Revenue, trailing twelve months · to Q2 2026 · +6.4% against the twelve months before

Net income: $847M
Net income · +1.3% year on year · trailing twelve months to Q2 2026
Free cash flow: $1.61B
Free cash flow · +25% year on year · trailing twelve months to Q2 2026
Operating margin: 15%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for DVA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$14.0B	+6.4%	Q2 2026
Net income	$847M	+1.3%	Q2 2026
EPS	$12.15	+20%	Q2 2026
Operating margin	15%	n/a	Q2 2026
Net margin	6.0%	n/a	Q2 2026
ROE	−116%	n/a	Q2 2026
ROA	4.5%	n/a	Q2 2026
ROIC	18%	n/a	Q2 2026
Free cash flow	$1.61B	+25%	Q2 2026
P/E	14.8	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.